Novo Nordisk ASWBO:NNO2 -1.23%71 Operating Cash Flow per Share is €3.57 as of Mar. 2026. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.14 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 758 Drug Manufacturers companies, Novo Nordisk AS ranks better than 60.69% on this metric.
Novo Nordisk AS's operating cash flow per share for the
three
months ended in Mar. 2026 was €0.72.
Novo Nordisk AS's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.57.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Novo Nordisk AS was -9.60% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.80% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Novo Nordisk AS's Operating Cash Flow per Share or its related term are showing as below:
WBO:NNO2'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -46.4 Med: 16.5 Max: 136.2
Current: 15.5
During the past 13 years, Novo Nordisk AS's highest 3-Year average Operating Cash Flow per Share Growth Rate was 136.20% per year. The lowest was -46.40% per year. And the median was 16.50% per year.
WBO:NNO2's 3-Year OCF Growth Rate is ranked better than 60.69% of 758
companies
in the Drug Manufacturers industry
Industry Median: 7.3
vs WBO:NNO2: 15.50
Novo Nordisk AS Operating Cash Flow per Share Related Terms
Novo Nordisk AS Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS Operating Cash Flow per Share Chart
WBO:NNO2 vs LLY, JNJ, ABBV: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of €3.57 mean?
Novo Nordisk AS (WBO:NNO2) has a Operating Cash Flow per Share of €3.57 as of Mar. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Novo Nordisk AS and its competitors. According to the industry distribution chart, Novo Nordisk AS ranks #298 out of 758 companies in the Drug Manufacturers industry, placing it in the top 39.3%.
Is Novo Nordisk AS's Operating Cash Flow per Share too high?
Novo Nordisk AS's current Operating Cash Flow per Share is €3.57. Based on the distribution chart, Novo Nordisk AS ranks #298 out of 758 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Operating Cash Flow per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #298 out of 758 companies for Operating Cash Flow per Share. This puts Novo Nordisk AS in the upper half of its industry. The industry median Operating Cash Flow per Share is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.30, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Operating Cash Flow per Share is €3.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.14, compared to a current price of €43.06 — trading 64.2% below its estimated fair value. The current Operating Cash Flow per Share is €3.57. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Operating Cash Flow per Share is €3.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €43.06 is trading 64.2% below its estimated GF Value™ of €120.14.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
Operating Cash Flow per Share: €3.57
GF Value™: €120.14 vs. price of €43.06 (64.2% below fair value)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score
Get the complete analysis for WBO:NNO2
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
